Wondered

In Part 2 of our two-part intelligence briefing on BlossomHill Therapeutics (NASDAQ: BLSM), we transition from Dr. Jean Cui’s foundational chemistry legacy to a deep-dive analysis of BlossomHill’s three clinical & preclinical assets, financial structure, trial safety nuances, and long-term valuation potential.

Fresh off an upsized $150M NASDAQ IPO pricing the company at $490M, BlossomHill is deploying a $254M cash balance to advance three radical macrocyclic candidates through oncology’s most stubborn biological crises.

What We Cover in Part 2:

- BH-30643 (EGFR C797S): Non-covalent conformation-selective macrocycle achieving a 0.54 nM IC50 against triple mutant L858R/T790M/C797S vs >1,000 nM for Osimertinib (Tagrisso). SOLARA Phase 1/2 clinical data.

- BH-30236 (Alternative Splicing in Leukemia): CLK1/2/4 inhibitor modulating RNA splicing in AML & MDS.

- BH-501284 (Pan-KRAS): Switch-II pocket pseudo-irreversible inhibitor with a 54-hour target residence half-life (vs 1.4 hours for AMG-410). Sub-nanomolar potency across G12C/D/V/S/A while sparing WT HRAS/NRAS.

- Financial Architecture & Valuation: From a $4.4M seed valuation in 2020 to $490M IPO pricing, analyzing the $254M cash runway extending into Q1 2028.

- Risk Analysis & Safety Scrutiny: Deconstructing the safety signal, execution burden across 3 global programs with 63 employees, and competition from main competitors.

Timestamps:

00:00 Introduction to BlossomHill's 3-Asset Pipeline

00:19 BH-30643: Non-Covalent Conformation Selectivity vs Tagrisso Resistance

05:44 BH-30236: Targeting CLK Kinases & Alternative Splicing in Leukemia

09:52 BH-501284: The Audacious Pan-KRAS Switch-II Inhibitor

15:19 Financial Evolution: From $4.4M Seed Valuation to $490M Nasdaq IPO

18:38 Key Catalysts & Milestone Calendar (2026-2027)

19:54 Risk Analysis: Operational Strain, FDA Safety Scrutiny & Competition

24:40 Conclusion: Translating Atomic Chemistry into Patient Survival

In Part 1 of our two-part intelligence briefing on BlossomHill Therapeutics (NASDAQ: BLSM), we trace the origins of one of oncology’s most formidable drug-hunting teams and deconstruct the three biological resistance crises they set out to solve.

Before raising a $150M upsized IPO, BlossomHill’s co-founder and CEO, Dr. Jingrong Jean Cui, earned legendary status in medicinal chemistry. As the inventor behind three FDA-approved targeted drugs: Crizotinib (Xalkori), Lorlatinib (Lorbrena), and Repotrectinib (Augtyro), she built Turning Point Therapeutics from scratch to its $4.1 billion acquisition by Bristol Myers Squibb.

What We Cover in Part 1:

00:00 BlossomHill IPO: A $150 Million Bet on Solving Cancer Resistance

01:38 Dr. Jean Cui: From Carbohydrate Chemistry at Ohio State to Biotech Founder

03:53 The Pfizer Invention: Crizotinib (Xalkori) and Structure-Based Drug Design

05:29 The Lorlatinib Breakthrough: Bending Molecules into Rings to Beat Resistance

07:49 Turning Point Therapeutics: Repotrectinib and the $4.1 Billion BMS Acquisition

09:15 Founding BlossomHill in June 2020: The Stealth 3-Target Thesis

11:46 The Gefitinib Paradox: How Precision Oncology Was Born Retrospectively

14:01 The EGFR Arms Race: From T790M Gatekeeper to $7.3B Osimertinib (Tagrisso)

16:48 The C797S Crisis: Why 16,000 Annual Patients Face Zero Oral Options

19:14 Why Was KRAS Undruggable for 40 Years? From Switch-II to Pan-KRAS

22:01 Alternative Splicing in AML & MDS: Overcoming Venetoclax Relapse

24:59 BlossomHill's 3-Asset Macrocyclic Platform: Deploying BH-30643 Against C797S

(Stay tuned for Part 2, where we dive into BlossomHill’s three clinical assets: BH-30643, BH-30236, and BH-501284, the competitive scorecard, and the investment thesis.)

In Part 1, Vivek Ramaswamy built a decentralized capital allocation machine designed to withstand failure. But in Part 2, we answer the ultimate question: could the machine run faster without its founder?

In this concluding episode, Wondered explores how Roivant transformed from a $93 million seed startup into a $4.3 billion cash fortress sitting on over $13 billion in cumulative deal value:

[00:00] Introduction: Roivant Part 2 & The Vant Ecosystem Return on Investment

[02:05] What is the Vant Ecosystem? Full Census of Exits, Survivors, and Casualties

[03:00] The Major Exits: Bundle Deals, Mergers, Patent Settlement

[05:53] Active Subsidiaries

[07:19] The Casualties & Ruthless Pipeline Discipline

[10:04] Roivant's First Commercial Drug & The $1.2 Billion Divestiture

[12:31] The $7.1 Billion Sale: Pfizer Joint Venture & Roche Mega-Exit

[15:36] Capital Allocation Discipline: The $1.5 Billion Share Buyback Program

[18:16] The Immunovant Crisis: Corporate Takeover & Batoclimab Phase 3 Trial Failure

[23:21] The $2.25 Billion Moderna Patent Settlement: Monetizing LNP Delivery Technology

[26:18] What is the "Big Orphan" Strategy?

[29:04] Summary & Conclusion: From $93M Seed to $13B+ Deal Value

Big Pharma often shelves good drugs. Not because the science failed but because priorities shifted, executives left, or a molecule didn't fit this quarter's strategy.

A 28 years old biotech investor at QVT Financial noticed this pattern. In 2014, he founded Roivant Sciences, a company built entirely around exploiting that inefficiency. The name said it all: ROI-vant. Return on Investment.

In this episode, Wondered trace the full origin story:

- How Ramaswamy went from Harvard valedictorian to Yale Law to hedge fund partner, and what he learned that no one else was acting on;

- The radical "Vant" model: a decentralized hub-and-spoke architecture built on four pillars: incentive alignment, shared services, ruthless pipeline discipline, and financial ring-fencing;

- The Axovant stress-test: a $5M shelved Alzheimer's drug, a $3B IPO, a catastrophic Phase III failure, and why Roivant walked away completely fine;

- The $3 billion Sumitomo Alliance: how Ramaswamy bundled five subsidiaries and sold them to a desperate Japanese pharma giant facing a patent cliff;

- The leadership transition: why Ramaswamy voluntarily handed the keys to operator Matt Gline and what happened next;

- The SPAC merger that took Roivant public at a $7.3 billion market cap in October 2021;

TIMESTAMPS

00:00 | Introduction: How Roivant Sciences Disrupted Biotech

02:48 | Vivek Ramaswamy's Origin Story: Harvard to Hedge Fund

08:27 | What is the Vant Model? The 4 Pillars of Roivant's Strategy

15:54 | The Axovant Stress-Test: A $3 Billion Alzheimer's Drug Crash

24:12 | The $3 Billion Sumitomo Alliance Deal Explained

29:25 | Leadership Transition: Vivek Ramaswamy Steps Down

31:39 | Scaling Biotech AI: Silicon Therapeutics & Datavant Merger

33:20 | The SPAC Merger: How Roivant Sciences Went Public ($7.3B)

35:42 Conclusion & What's Next in Part 2

How does a failed HIV pill transform into a $10 billion immunology biotech empire, only to see its stock crash on the exact day it releases best-in-class clinical data? In this deep-dive documentary episode, we unpack the wild, 1,800% surging ride of Abivax (NASDAQ: ABVX), and explore the incredible origin story of Obefazimod, a first-in-class small molecule that was abandoned as an antiviral but unexpectedly discovered to be a powerhouse treatment for Inflammatory Bowel Disease (IBD).

At the heart of Abivax’s meteoric rise is a groundbreaking scientific mechanism: the upregulation of microRNA-124 (miR-124), which restores immunological homeostasis without the lethal treatment related adverse events that plague competing JAK inhibitors. We break down the massive $30 billion total addressable market (TAM) for IBD treatments, the competitive landscape, and the intense Wall Street speculation that culminated in rumors of a massive $17.4 billion buyout.

But the biotech sector is notoriously volatile, and Abivax is no exception. We analyze the dramatic market reaction to their Phase 3 maintenance data, where despite achieving an unprecedented 51% clinical remission rate, ABVX stock plummeted 40% due to Wall Street panic over a handful of clinically unrelated cancer cases. Finally, we look ahead to the company's fully funded runway and their highly anticipated New Drug Application (NDA) submission to the FDA in late 2026.

Whether you are a biotech investor, a medical science enthusiast, or just love a high-stakes corporate drama, this episode reveals the true story behind the ticker.

[01:39] The Origins (2013): Abivax's founding, the Truffle Capital roll-up, and the 50/50 IP split with CNRS.

[03:14] The HIV Ambition: The initial goal for ABX464 as a functional cure for HIV and its subsequent clinical failure.

[04:57] The Accidental Discovery: The pivot from virology to immunology after discovering profound anti-inflammatory properties in a mouse model.

[06:41] The Nightmare of IBD: Understanding the cascading breakdown of immune tolerance in the gut.

[07:49] Crohn's vs. Ulcerative Colitis.

[12:00] The Biological Differentiator: How Obefazimod binds to the Cap-Binding Complex to upregulate microRNA-124 (miR-124).

[16:04] The Treat-to-Target Paradigm: The industry's shift away from symptom relief toward deep, microscopic healing (HEMI) .

[17:53] Phase 2b & "De Novo" Remission: Astounding 2-year durability data and the revelation that 43% of initial non-responders eventually achieved healing .

[19:52] The Phase 3 ABTECT Program: Testing the drug on the hardest-to-treat patients in the world.

[20:36] July 2025 Induction Data: top-tier efficacy and clean safety data.

[22:01] The $30 Billion Prize: The staggering financial implications as analysts project $5B in peak sales for Obefazimod.

[23:24] The 1,800% Stock Surge: Abivax's valuation crosses $10 billion, supercharged by whispers of a $17.4 billion Eli Lilly buyout.

[25:59] The June 2026 Maintenance Data: Obefazimod posts a landmark 51.3% remission rate, but the stock inexplicably crashes.

[28:10] The Strategic Brilliance of 25mg: the lower dose maintained efficacy while remaining completely free of the non-skin cancers.

[30:07] The Countdown to FDA Approval: Battered but fully funded with runway into late 2027, the countdown begins for the Q4 2026 NDA submission.

What does a failed 1990s medical imaging company have to do with the modern vaping epidemic? Everything. In this episode, we trace the incredible 35-year corporate evolution of Achieve Life Sciences (ACHV). We uncover how two biotech veterans orchestrated a $2 million arbitrage play, took over a public shell via a reverse merger, and positioned a 50-year-old Eastern European smoking pill to completely disrupt the $11 billion nicotine cessation market.

We break down the brilliant biology of cytisinicline, explore the macro shift and market vacuum created by Pfizer's Chantix recall, and reveal the recent $354 million Wall Street bailout that reset the company.

Plus, discover why the FDA just handed Achieve one of the rarest regulatory tickets in America: the inaugural Commissioner's National Priority Voucher (CNPV).

[00:32] How a plant-based extract secured the ultra-rare Commissioner's National Priority Voucher alongside giants like Eli Lilly?

[04:24] How Does Cytisinicline Work? The dual-acting mechanism of action that blocks nicotine reward and eases withdrawal cravings.

[08:12] The $2 million upfront clinical arbitrage play: Securing global rights from Sopharma.

[10:31] The Reverse Takeover: Executing a merger to fast-track Nasdaq access and Wall Street capital.

[13:14] Corporate Origins (1991): Tracing the ACHV public shell back to its failed ultrasound imaging technology.

[15:30] How the OncoGenex Oncology Collapse paved the way for the Achieve merger.

[17:41] ORCA-1 Clinical Trial Results: Cytisinicline achieves a 54% smoking quit rate at Week 4.

[20:37] Cytisinicline data: Analyzing the 98% clinical adherence rate, the lack of nausea, and the real-world challenge of TID dosing.

[23:33] The Vaping Epidemic & Chantix Recall: A billion-dollar market vacuum in nicotine cessation.

[26:17] FDA Breakthrough Therapy Designation: Cytisinicline as the first potential FDA-approved medical treatment for vaping cessation.

[27:24] FDA OAI Manufacturing Delay: How Achieve turned an inspection failure into a company reset in 2026.

[34:23] Market Size & ACHV Catalysts: Projecting the $11 billion market opportunity, $800M peak sales estimates, and the 2027 commercial launch timeline.

Disclaimer:

Health: For informational purposes only. Not a substitute for professional medical advice.

Financial: Does not constitute financial advice and should not be used as the basis for investment decisions.

Regulatory: Not intended to influence or impact any regulatory actions or processes.

How did Revolution Medicines conquer the "undruggable" KRAS protein? This episode deconstructs the rise of Revolution Medicines (RVMD), a biotech company that paired contrarian science with elite financial engineering to shatter a 40-year oncology stalemate.

Time | Topic

02:33 | Why was the KRAS protein considered undruggable for 40 years?

08:18 | How did Revolution Medicines pivot from anti-fungals to oncology?

15:20 | What are the limitations of first-generation KRAS OFF-state inhibitors like sotorasib & adagrasib?

26:53 | How was the RAS(ON) Tri-Complex molecular glue turned into an effective anti-cancer drug?

35:34 | How did Revolution Medicines secure $billions during the “Biotech Winter”?

44:41 | What does the 0.40 hazard ratio mean for pancreatic cancer survival?

Disclaimer:

Health: For informational purposes only. Not a substitute for professional medical advice.

Financial: Does not constitute financial advice and should not be used as the basis for investment decisions.

Regulatory: Not intended to influence or impact any regulatory actions or processes.